A Phase II Study of Sorafenib in Combination with Cisplatin and 5-fluorouracil in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

TY - JOUR

T1 - A Phase II Study of Sorafenib in Combination with Cisplatin and 5-fluorouracil in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

AU - Sun, Yuanlu (April)

AU - Xue, Cong

AU - Yu, Qitao

AU - Pan, Jian-Ji

AU - Zhang, Li

N1 - Background: Nasopharyngeal carcinoma (NPC) is a disease with distinctive epidemiology and clinical behavior compared with Head and neck cancer (HNC) and more common in South-East Asia. Sorafenib monotherapy has been shown modest anticancer activity in HNC and NPC ( C Elser et al; JCO 2007).

PY - 2012

Y1 - 2012

UR - https://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.5538

U2 - 10.1200/jco.2012.30.15_suppl.5538

DO - 10.1200/jco.2012.30.15_suppl.5538

M3 - Article

VL - 30

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -